Fecal Incontinence - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 45 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Fecal Incontinence - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Fecal Incontinence - Pipeline Review, H2 2014', provides an overview of the Fecal Incontinence's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fecal Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fecal Incontinence and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fecal Incontinence
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Fecal Incontinence and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Fecal Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fecal Incontinence pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fecal Incontinence
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fecal Incontinence pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fecal Incontinence Overview 6
Therapeutics Development 7
Pipeline Products for Fecal Incontinence - Overview 7
Pipeline Products for Fecal Incontinence - Comparative Analysis 8
Fecal Incontinence - Therapeutics under Development by Companies 9
Fecal Incontinence - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Fecal Incontinence - Products under Development by Companies 12
Fecal Incontinence - Companies Involved in Therapeutics Development 13
Cook Medical Incorporated 13
Norgine B.V. 14
RDD Pharma Ltd. 15
Juventas Therapeutics, Inc. 16
Celogos 17
S.L.A. Pharma AG 18
Innovacell Biotechnologie AG 19
Fecal Incontinence - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
RCD-2 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
methoxamine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
phenylephrine hydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
phenylephrine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ICEF-15 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Autologous Muscle Derived Cell Transplantation - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
JVS-100 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Fecal Incontinence - Recent Pipeline Updates 40
Fecal Incontinence - Dormant Projects 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products under Development for Fecal Incontinence, H2 2014 7
Number of Products under Development for Fecal Incontinence - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Fecal Incontinence - Pipeline by Cook Medical Incorporated, H2 2014 13
Fecal Incontinence - Pipeline by Norgine B.V., H2 2014 14
Fecal Incontinence - Pipeline by RDD Pharma Ltd., H2 2014 15
Fecal Incontinence - Pipeline by Juventas Therapeutics, Inc., H2 2014 16
Fecal Incontinence - Pipeline by Celogos, H2 2014 17
Fecal Incontinence - Pipeline by S.L.A. Pharma AG, H2 2014 18
Fecal Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Fecal Incontinence Therapeutics - Recent Pipeline Updates, H2 2014 40
Fecal Incontinence - Dormant Projects, H2 2014 43